This opportunity is now closed.

Self-funded MRes opportunity

Assay development for apelin peptides and insights into variability in metabolic disease

Subject: Biomedical Sciences


Summary

Adipose tissue is now recognised as much more than an excess energy storage depot but is in fact a metabolically active organ [1].  Several adipokines signal to other tissues to help coordinate physiological processes including energy homeostasis [1].  Imbalanced adipokine production is thought to contribute to the pathogenesis of obesity related Type 2 diabetes and cardiovascular disease (CVD) complications [2]. Adipokines upregulated in obesity, including adiponectin and apelin, can exert anti-inflammatory and cardio-protective effects [3], whereas others impair cardiovascular function [3].

This project will focus on apelin, which is known to exist in various isoforms (processed from a larger apelin-77 precursor), including apelin-36, apelin-17, (pGlu)apelin-13 and apelin-13. Apelin-13 has multiple biological actions mediated through its cognate APJ receptor. There is growing interest in the role of apelin in metabolic diseases including T2DM, obesity and CVD [4,5]. A recent meta-analysis showed low circulating apelin concentrations are associated with a higher risk of hypertension [6].  Coronary heart disease subjects were reported to have lower apelin concentrations compared to healthy controls [7,8].  Despite this, relatively little is known about the role of apelin in the pathophysiology of obesity and diabetes.  Some studies show that circulating apelin concentrations are elevated in T2DM and obesity, but others suggest that it is lower [9].

Experimental Design:

The current research study will improve our understanding of the pathophysiology of apelin, while assessing its utility as a disease biomarker in stratified human clinical samples by quantifying various apelin isoforms in plasma samples under a variety of conditions. A HPLC method with MS verification will be used to examine peptide recovery from mouse plasma samples.

*Examining the stability and half-life of natural isoforms of apelin (e.g. apelin-36, (pGlu)apelin-13 and apelin-13) in mouse plasma in vitro using a HPLC based assay with peptide identification by mass spectrometry.

*To determine the recovery of apelin isoforms following sample spiking to determine assay recovery, variability and sensitivity.

*Measurement of apelin isoforms in human subjects at risk of diabetes (e.g. pre-diabetes and obese populations BMI>25 kg/m2) or during the time course of an OGTT (e.g. DexLife Study).

Methods:

A reversed phase HPLC method will be used to examine peptide recovery from mouse plasma samples following spiking with synthetic forms of the naturally occurring peptides. An ELISA assay apelin-13 will be used to measure apelin in human plasma/serum samples.  LC-MS and MALDI-TOF mass spectrometry techniques will be developed to look at the quantification of various isoforms using spiked plasma samples.

Skills required of applicant:

The applicant should ideally have good practical laboratory, computer and communication skills and show enthusiasm and commitment to work diligently on all aspects the research project. A background in biomedical sciences, biochemistry, pharmacology or a related subject would be desirable.

References:

[1]    Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-920.

[2]    Shibata R, et al. The role of adipokines in cardiovascular disease. J Cardiol 2017;70(4):329-334.

[3]    Smekal A, et al. Adipokines and cardiovascular disease: A comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017;161:31– 40.

[4]    Cudnoch Jedrzejewska A, et al. The role of apelin in pathogenesis of Cardiovascular diseases and metabolic disorders].  
Kardiol Pol 2011;69 Suppl 3:89 –93.

[5]    Castan-Laurell I, et al. Apelin, diabetes, and obesity. Endocrine 2011;40:1–9.

[6]    Xie H, et al. Lowered circulating apelin is significantly associated with an increased risk for hypertension: a meta-analysis. Clin Exp Hypertens 2017;39:435– 440.

[7]   Chen T, et al. Association of apelin and apelin receptor with the risk of coronary artery disease:  A meta-analysis of observational studies. Oncotarget 2015;8(34).

[8]   Zhang BH, et al. Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels 2014;29:679 – 689.

[9]   Castan-Laurell I, et al. Apelin, a novel adipokine over-produced in obesity: Friend or foe? Mol Cell Endocrinol 2005;245:7–9

[10]  O'Harte FPM, et al. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochem Pharmacol 2017;15;146:165-17


Essential criteria

  • Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC)


Funding

This is a self-funded MRes opportunity.


Other information


The Doctoral College at Ulster University


Reviews

My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video  

Completing the MRes provided me with a lot of different skills, particularly in research methods and lab skills.

Michelle Clements Clements - MRes - Life and Health Sciences

Watch Video  

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key dates

Submission deadline
Friday 31 May 2019


Campus

Coleraine campus

Coleraine campus
Our coastal and riverside campus focussing on science and health


Contact supervisor

Professor Finbarr O'Harte


Other supervisors


Applying

Apply Online

Related Funded Opportunities in: Biomedical Sciences ,

Novel amphibian skin peptide-analogues for the treatment of type-2 diabetes

Closing date:
Wednesday 18 September 2019
Subject:
Biomedical Sciences

 View Details

Using the Eye to Predict risk for Cardiovascular disease- The Living Lab

Closing date:
Friday 27 September 2019
Subject:
Biomedical Sciences|Engineering

 View Details

Diabetes

Subject:
Biomedical Sciences

 View Details

Genomic Medicine

Subject:
Biomedical Sciences

 View Details

Stratified Medicine

Subject:
Biomedical Sciences

 View Details

The regulation of rhamnolipid biosynthesis in Burkholderia thailandensis.

Closing date:
Tuesday 1 September 2020
Subject:
Biomedical Sciences

 View Details

Optometry and Vision Science

Subject:
Biomedical Sciences

 View Details

The production of rhamnolipid biosurfactant by Pseudomonas aeruginosa growing in biofilms.

Closing date:
Tuesday 1 September 2020
Subject:
Biomedical Sciences

 View Details

MRes in Biomedical Sciences

Subject:
Biomedical Sciences

 View Details

The design and analysis of a novel photo-activated antimicrobial system

Closing date:
Tuesday 1 September 2020
Subject:
Biomedical Sciences

 View Details

Molecular Pathology of Glaucoma

Closing date:
Wednesday 1 January 2020
Subject:
Biomedical Sciences

 View Details